The global Spinal Muscular Atrophy (SMA) Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Spinal Muscular Atrophy (SMA), also known as spinal muscular atrophy, is a type of disease in which the degeneration of motor neurons in the anterior horn of the spinal cord leads to muscle weakness and muscular atrophy.The Spinal muscular atrophy drugs Can effectively alleviate the symptoms of the disease.
This report aims to provide a comprehensive presentation of the global market for Spinal Muscular Atrophy (SMA) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal Muscular Atrophy (SMA) Drugs. This report contains market size and forecasts of Spinal Muscular Atrophy (SMA) Drugs in global, including the following market information:
- Global Spinal Muscular Atrophy (SMA) Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global top five companies in 2022 (%)
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Oral Medicine Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Spinal Muscular Atrophy (SMA) Drugs include Biogen, Novartis and Genentech, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Spinal Muscular Atrophy (SMA) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Spinal Muscular Atrophy (SMA) Drugs Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Spinal Muscular Atrophy (SMA) Drugs Market Segment Percentages, by Type, 2022 (%)
- Oral Medicine
- Injection Medicine
Global Spinal Muscular Atrophy (SMA) Drugs Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Spinal Muscular Atrophy (SMA) Drugs Market Segment Percentages, by Application, 2022 (%)
Global Spinal Muscular Atrophy (SMA) Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Spinal Muscular Atrophy (SMA) Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Spinal Muscular Atrophy (SMA) Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Spinal Muscular Atrophy (SMA) Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Biogen
- Novartis
- Genentech
Outline of Major Chapters:
Chapter 1: Introduces the definition of Spinal Muscular Atrophy (SMA) Drugs, market overview.
Chapter 2: Global Spinal Muscular Atrophy (SMA) Drugs market size in revenue.
Chapter 3: Detailed analysis of Spinal Muscular Atrophy (SMA) Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments
by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments
by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Spinal Muscular Atrophy (SMA) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Spinal Muscular Atrophy (SMA) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Spinal Muscular Atrophy (SMA) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Spinal Muscular Atrophy (SMA) Drugs Overall Market Size
2.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Size: 2022 VS 2030
2.2 Global Spinal Muscular Atrophy (SMA) Drugs Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Spinal Muscular Atrophy (SMA) Drugs Players in Global Market
3.2 Top Global Spinal Muscular Atrophy (SMA) Drugs Companies Ranked by Revenue
3.3 Global Spinal Muscular Atrophy (SMA) Drugs Revenue by Companies
3.4 Top 3 and Top 5 Spinal Muscular Atrophy (SMA) Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Spinal Muscular Atrophy (SMA) Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Spinal Muscular Atrophy (SMA) Drugs Players in Global Market
3.6.1 List of Global Tier 1 Spinal Muscular Atrophy (SMA) Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Spinal Muscular Atrophy (SMA) Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Spinal Muscular Atrophy (SMA) Drugs Market Size Markets, 2022 & 2030
4.1.2 Oral Medicine
4.1.3 Injection Medicine
4.2 By Type - Global Spinal Muscular Atrophy (SMA) Drugs Revenue & Forecasts
4.2.1 By Type - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2018-2023
4.2.2 By Type - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2024-2030
4.2.3 By Type - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Spinal Muscular Atrophy (SMA) Drugs Market Size, 2022 & 2030
5.1.2 Baby
5.1.3 Child
5.1.4 Adult
5.2 By Application - Global Spinal Muscular Atrophy (SMA) Drugs Revenue & Forecasts
5.2.1 By Application - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2018-2023
5.2.2 By Application - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2024-2030
5.2.3 By Application - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Spinal Muscular Atrophy (SMA) Drugs Market Size, 2022 & 2030
6.2 By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue & Forecasts
6.2.1 By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2018-2023
6.2.2 By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2024-2030
6.2.3 By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Spinal Muscular Atrophy (SMA) Drugs Revenue, 2018-2030
6.3.2 US Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.3.3 Canada Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.3.4 Mexico Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Spinal Muscular Atrophy (SMA) Drugs Revenue, 2018-2030
6.4.2 Germany Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.4.3 France Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.4.4 U.K. Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.4.5 Italy Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.4.6 Russia Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.4.7 Nordic Countries Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.4.8 Benelux Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Spinal Muscular Atrophy (SMA) Drugs Revenue, 2018-2030
6.5.2 China Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.5.3 Japan Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.5.4 South Korea Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.5.5 Southeast Asia Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.5.6 India Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Spinal Muscular Atrophy (SMA) Drugs Revenue, 2018-2030
6.6.2 Brazil Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.6.3 Argentina Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue, 2018-2030
6.7.2 Turkey Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.7.3 Israel Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.7.4 Saudi Arabia Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
6.7.5 UAE Spinal Muscular Atrophy (SMA) Drugs Market Size, 2018-2030
7 Spinal Muscular Atrophy (SMA) Drugs Companies Profiles
7.1 Biogen
7.1.1 Biogen Company Summary
7.1.2 Biogen Business Overview
7.1.3 Biogen Spinal Muscular Atrophy (SMA) Drugs Major Product Offerings
7.1.4 Biogen Spinal Muscular Atrophy (SMA) Drugs Revenue in Global Market (2018-2023)
7.1.5 Biogen Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Spinal Muscular Atrophy (SMA) Drugs Major Product Offerings
7.2.4 Novartis Spinal Muscular Atrophy (SMA) Drugs Revenue in Global Market (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Genentech
7.3.1 Genentech Company Summary
7.3.2 Genentech Business Overview
7.3.3 Genentech Spinal Muscular Atrophy (SMA) Drugs Major Product Offerings
7.3.4 Genentech Spinal Muscular Atrophy (SMA) Drugs Revenue in Global Market (2018-2023)
7.3.5 Genentech Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Spinal Muscular Atrophy (SMA) Drugs Market Opportunities & Trends in Global Market
Table 2. Spinal Muscular Atrophy (SMA) Drugs Market Drivers in Global Market
Table 3. Spinal Muscular Atrophy (SMA) Drugs Market Restraints in Global Market
Table 4. Key Players of Spinal Muscular Atrophy (SMA) Drugs in Global Market
Table 5. Top Spinal Muscular Atrophy (SMA) Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Spinal Muscular Atrophy (SMA) Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Spinal Muscular Atrophy (SMA) Drugs Product Type
Table 9. List of Global Tier 1 Spinal Muscular Atrophy (SMA) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Spinal Muscular Atrophy (SMA) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Spinal Muscular Atrophy (SMA) Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Spinal Muscular Atrophy (SMA) Drugs Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Spinal Muscular Atrophy (SMA) Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Spinal Muscular Atrophy (SMA) Drugs Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2024-2030
Table 30. Biogen Company Summary
Table 31. Biogen Spinal Muscular Atrophy (SMA) Drugs Product Offerings
Table 32. Biogen Spinal Muscular Atrophy (SMA) Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Biogen Key News & Latest Developments
Table 34. Novartis Company Summary
Table 35. Novartis Spinal Muscular Atrophy (SMA) Drugs Product Offerings
Table 36. Novartis Spinal Muscular Atrophy (SMA) Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Novartis Key News & Latest Developments
Table 38. Genentech Company Summary
Table 39. Genentech Spinal Muscular Atrophy (SMA) Drugs Product Offerings
Table 40. Genentech Spinal Muscular Atrophy (SMA) Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Genentech Key News & Latest Developments
List of Figures
Figure 1. Spinal Muscular Atrophy (SMA) Drugs Segment by Type in 2022
Figure 2. Spinal Muscular Atrophy (SMA) Drugs Segment by Application in 2022
Figure 3. Global Spinal Muscular Atrophy (SMA) Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Spinal Muscular Atrophy (SMA) Drugs Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Spinal Muscular Atrophy (SMA) Drugs Revenue in 2022
Figure 8. By Type - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2018-2030
Figure 9. By Application - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2018-2030
Figure 10. By Type - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2018-2030
Figure 12. By Application - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2018-2030
Figure 14. By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2018-2030
Figure 15. By Country - North America Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2018-2030
Figure 16. US Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2018-2030
Figure 20. Germany Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 21. France Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2018-2030
Figure 28. China Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 32. India Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2018-2030
Figure 34. Brazil Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2018-2030
Figure 37. Turkey Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2018-2030
Figure 41. Biogen Spinal Muscular Atrophy (SMA) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Novartis Spinal Muscular Atrophy (SMA) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Genentech Spinal Muscular Atrophy (SMA) Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
